帕罗西汀联合阿立哌唑治疗躯体化障碍对照研究

目的 探讨帕罗西汀联合阿立哌唑治疗躯体化障碍的临床疗效和安全性.方法 将68例躯体化障碍患者随机为两组,每组34例,两组均晨口服帕罗西汀治疗,治疗组在此基础上每晚口服阿立哌唑治疗,观察8周.于治疗前及治疗2周、4周、6周、8周末采用汉密顿抑郁量表、汉密顿焦虑量表评定临床疗效,副反应量表评定不良反应.结果 治疗后两组汉密顿焦虑量表、汉密顿抑郁量表评分均较治疗前有显著下降(P＜0.01),同期治疗组均较对照组下降更显著(P＜0.05或0.01);治疗8周末,治疗组抗焦虑、抗抑郁有效率均显著高于对照组(P＜0.05).两组不良反应均轻微,副反应量表评分及不良反应发生率差异均无显著性(P＞0.05).结论 帕罗西汀联合阿立哌唑治疗躯体化障碍患者具有增效作用,疗效显著,起效更快,且不增加不良反应,安全性高,依从性好,显著优于单用帕罗西汀治疗.

A control study of paroxetine combined with aripiprazole in the treatment of somatization disorder

Objective To explore the efficacy and safety of paroxetine combined with aripiprazole in the treatment of somatization disorder（SD）. Methods Sixty eight with SD patients were randomly divided into two groups of 34 ones each, both groups took orally paroxetine in the morning, treatment group was plus oral aripiprazole quaquc nocte for 8 weeks. Efficacies were assessed with the HamiltonDepression Scale （ HAMD ） and Hamilton Anxiety Scale （ HAMA ） and adverse reactions with the Treat ment Emergent Symptom Scale （ TESS ） before treatment and at the end of the 2nd , 4th , 6th and 8th week. Results After treatment the HAMD and HAMA scores of both groups lowered more significantly com- pared with pretreatment （P〈0.01）, so did those in treatment than in control group （P〈0.05 or 0.01） at the end of the 8th week effective rates of antianxiety and antidepression were significantly higher in treat- men1 than in control group （P〈0.05）. Adverse reactions of both groups were mild, there were no signifi cant group differences in TESS score and incidences of adverse reactions （P〉0.05）. Conclusion Paroxe- tine combined with aripiprazole in the treatment of somatization disorder has a synergistic effect, evident efficacy, higher safety and better compliance, takes effect more rapidly, can＇t increase adverse reactions, has an advantage over single paroxetine.